Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[2.]
R. Queiro Silva, J.C. Torre Alonso, T. Tinturé Eguren, I. López Laguna.
A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis.
Ann Rheum Dis, 62 (2003), pp. 68-70
[3.]
D. Kane, L. Stafford, B. Bresnihan, O. Fitzgerald.
A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.
Rheumatology, 42 (2003), pp. 1460-1468
[4.]
N. Pipitone, G.H. Kingsley, A. Manzo, D.L. Scott, C. Pitzalis.
Current concepts and new developments in treatment of psoriatic arthritis.
Rheumatology, 42 (2003), pp. 1138-1148
[5.]
M. Dougados, S. Van der Linden, M. Leirisalo-Repo, B. Huitfeldt, R. Jhulin, E. Veys, et al.
Sulfasalazine in the treatment of spondyloarthropathy.
Arthritis Rheum, 38 (1995), pp. 618-627
[6.]
D.O. Clegg, D.J. Reda, E. Mejias, G.W. Cannon, M.H. Weisman, T. Taylor, et al.
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis.
Arthritis Rheum, 39 (1996), pp. 2013-2020
[7.]
D.O. Clegg, D.J. Reda, M. Abdellatif.
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies.
Arthritis Rheum, 42 (1999), pp. 2325-2329
[8.]
R.L. Black, W.M. O’Brien, E.J. Van Scott, R. Auerbach, A.Z. Eisen, J.J. Bunim.
Methotrexate therapy in psoriatic arthritis.
JAMA, 189 (1964), pp. 743-747
[9.]
R.F. Willkens, H.J. Williams, J.R. Ward, M.J. Egger, J.C. Reading, P.J. Clements, et al.
Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis.
Arthritis Rheum, 27 (1984), pp. 376-381
[10.]
L.R. Espinoza, L. Zakraoui, C.G. Espinoza, F. Gutiérrez, L.J. Jara, L.H. Silveira, et al.
Psoriatic arthritis: clinical response and side effects to methotrexate therapy.
J Rheumatol, 19 (1992), pp. 872-877
[11.]
J. Belzunegui, J.J. Intxausti, J.R. De Dios, L. López-Domínguez, R. Queiro, C. González, et al.
Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate.
Clin Exp Rheumatol, 19 (2001), pp. 727-730
[12.]
M. Abu-Shakra, D.D. Gladman, J.C. Thorne, J. Long, J. Gough, V.T. Farewell.
Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome.
J Rheumatol, 22 (1995), pp. 241-245
[13.]
C. Salvarani, P. Macchioni, I. Olivieri, A. Marchesoni, M. Cutolo, G. Ferracioli, et al.
A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.
J Rheumatol, 28 (2001), pp. 2274-2282
[14.]
P. Macchioni, I. Boiardi, T. Cremonesi, B. Battistel, M. Casadei-Maldini, E. Beltrandi, et al.
The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A.
Rheumatol Int, 18 (1998), pp. 27-33
[15.]
A. Spadaro, V. Riccieri, A. Sili-Scavalli, F. Sensi, E. Taccari, A. Zoppini.
Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.
Clin Exp Rheumatol, 13 (1995), pp. 589-593
[16.]
J.P. Kaltwasser, P. Nash, D. Gladman, C.F. Rosen, F. Behrens, P. Jones, et al.
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis.
Arthritis Rheum, 50 (2004), pp. 1939-1950
[17.]
A.D. Fraser, A.W. Van Kuijk, R. Westhovens, Z. Karim, R. Wakefield, A.H. Gerards, et al.
A randomised, double-blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis.
Ann Rheum Dis, (2004),
[18.]
C. Gómez Vaquero, J. Rodríguez Moreno, S. Ros, R. Marcos, J. Fiter, D. Roig Escofet.
Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment.
Br J Rheumatol, 35 (1996), pp. 564-567
[19.]
A. Spadaro, E. Taccari, B. Mohtadi, V. Riccieri, F. Sensi, A. Zoppini.
Lifetable analysis of cyclosporin A in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs.
Clin Exp Rheumatol, 15 (1997), pp. 609-614
[20.]
I. Ujfalussy, E. Koo, M. Sesztak, P. Gergely.
Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
Z Rheumatol, 62 (2003), pp. 155-160
Copyright © 2005. Elsevier España S.L. Barcelona
